VEXAS Syndrome
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
1 programMulticenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial CollectionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbMulticenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
Clinical Trials (1)
Total enrollment: 500 patients across 1 trials
NCT06377462Bristol Myers SquibbMulticenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
Start: Mar 2024Est. completion: Dec 2030500 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 500 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.